Overview

IBP-9414 for the Prevention of Necrotizing Enterocolitis - The Connection Study

Status:
Recruiting
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
IBP-9414 will be evaluated in preterm infants with a birth weight of 500-1500g, compared to placebo with regards to efficacy and safety in the prevention of necrotizing enterocolitis.
Phase:
Phase 3
Details
Lead Sponsor:
Infant Bacterial Therapeutics